产品中心
-
产品货号
产品名称
规格
销售价
会员价
货期
产地
订购
-
CI95
Recombinant Human F9/Coagulation factor IXchain/Coagulation factor IXa heavy chain
10ug
936
842.4
现货
国产
-
CI95
Recombinant Human F9/Coagulation factor IXchain/Coagulation factor IXa heavy chain
50ug
3520
3168
现货
国产
-
CI95
Recombinant Human F9/Coagulation factor IXchain/Coagulation factor IXa heavy chain
500ug
12320
11088
现货
国产
-
CI95
Recombinant Human F9/Coagulation factor IXchain/Coagulation factor IXa heavy chain
1mg
17600
15840
现货
国产
- 产品简介
- 使用说明
- 相关产品
- 参考文献
- 购买咨询
Catalog# CI95 Source Human cells Description Recombinant Human F9 is produced with our mammalian expression system in human cells. The target protein is expressed with sequence (Thr29-Thr461) of Human F9 fused with a polyhistidine tag at the C-terminus. Names F9/Coagulation factor IX/Christmas factor/Plasma thromboplastin component/PTC/Coagulation factor IXa light chain/Coagulation factor IXa heavy chain Accession # P00740 Formulation Lyophilized from a 0.2 μM filtered solution of 20mM TrisHCl,150mM NaCl,10% Glycerol,pH8.0 Shipping The product is shipped at ambient temperature. Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in 2X PBS.
Please aliquot the reconstituted solution_x0000__x0016__x0000_u_x0000_u_x0000__x0014__x0000__x0016__x0000_v_x0000_v_x0000__x0000__x0000_ _x0000_v_x0000_v_x0000__x0014__x0000__x0016__x0000_䠀ŒѦStorage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 4 months.Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. Endotoxin Less than 0.1 ng/µg (1 IEU/µg). Amino Acid Sequence TVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVD GDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCT EGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFND FTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETE HTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYV SGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTE VEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTVDHHHHHH*Background Coagulation factor IX（F9), is a member of the peptidase S1 family. It contains two EGF-like domains, a Gla domain and a peptidase S1 domain. It is primarily expressed in the liver and secreted in plasma. Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa. Mutations in position 43 and 46 prevents cleavage of the propeptide, mutation in position 93 probably fails to bind to cell membranes, mutation in position 191 or in position 226 prevent cleavage of the activation peptide. Mutations of human F9 can result in thrombophilia and recessive X-linked hemophilia B (HEMB). An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma.